#United States #Salt Lake City #peptide delivery #InstaMed #Tracy Gibbs

New Leadership at InstaMed Pharmaceuticals

InstaMed® Pharmaceuticals, a pioneering company in the field of biotechnology, has announced the appointment of Dr. Tracy Gibbs as the Chief Executive Officer (CEO). This strategic move reflects the company's commitment to revolutionizing peptide delivery methods, particularly through its patented InstaRelease® oral dissolving strip technology. As the company gears up for a groundbreaking launch on August 3, where it will unveil five new non-injectable peptide products, Dr. Gibbs' leadership is poised to take the company to new heights in the evolving biopharma landscape.

A Milestone for the Company

Founded just 14 months ago, InstaMed has already garnered attention for its innovative approach to peptide therapies. Dr. Gibbs, who is well-respected in the industry for his expertise in nutrient absorption science and advanced delivery systems, stepped into his role at a pivotal moment. Very soon, InstaMed’s offerings will provide patients with an alternative to traditional injectable therapies, which have been noted for their inconveniences, such as the need for refrigeration and the discomfort associated with injections.

The Need for Change

The demand for solutions in longevity, metabolic health, cognitive function, and recovery continues to rise. However, many patients have been deterred by the limitations posed by injectable therapies. InstaMed's focus on oral dissolvable delivery methods could change this narrative, potentially revolutionizing how patients receive their medications. By utilizing its oral dissolvable strip technology, InstaMed enables active compounds to be absorbed efficiently through the oral mucosa, effectively bypassing gastrointestinal degradation and increasing overall efficacy.

Clinical Studies Validation

Recently, InstaMed validated its platform through a successful double-blinded pharmacokinetic study. The study showed that the use of oral dissolving strips resulted in faster absorption rates and more stable circulating peptide levels compared to conventional delivery methods. Dr. Gibbs emphasized that, “The peptide industry is evolving rapidly, and expanding patient access depends on delivery technologies that are both effective and convenient.” He pinpointed that with rigorous scientific backing, patients can finally achieve therapeutic effectiveness without the discomfort of injections.

Exciting Product Launch Ahead

On August 3, 2026, InstaMed will officially launch an exciting range of products, including:

• - Ultratrutide: A groundbreaking Quad Agonist peptide targeting multiple metabolic pathways.
• - KLOW: A formulation to promote metabolic wellness and help with weight management.
• - Delta Sleep-Inducing Peptide (DSIP): Tailored to improve sleep architecture.
• - MOTS-c: A mitochondrial-derived peptide focusing on energy production and metabolic performance.
• - Semax and Selank: Advanced neuropeptides designed to enhance cognitive function and stress resilience.

With nine pending patents, InstaMed has diligently focused on cultivating significant partnerships across various sectors, including medical practices and wellness clinics. The company has observed an impressive month-over-month growth rate of approximately 18-20%, indicating a rising demand for its innovative delivery approach.

Future Expansion Plans

InstaMed is not just resting on its laurels. With ongoing international distribution plans in regions like Southeast Asia, Latin America, and the Middle East, the company is poised for remarkable growth. Along with expanding manufacturing capabilities, InstaMed will conduct further clinical validation studies for its emerging products. The broader goal remains clear: to make advanced peptide solutions widely available to a global market, ensuring accessibility while maintaining high standards in therapeutic performance.

Dr. Gibbs remains enthusiastic about engaging with the media and stakeholders about the transformative potential of non-injectable peptide delivery technologies. He is eager to discuss the innovative pipeline leading up to the anticipated launch, along with recent findings from pharmacokinetic research.

Conclusion

The appointment of Dr. Tracy Gibbs as CEO marks a significant turning point for InstaMed Pharmaceuticals as it embarks on its exciting journey in the field of biotechnology. With its innovative approach and commitment to making peptide therapies more accessible and convenient, InstaMed is set to redefine patient experiences and outcomes in medical treatments. As we await the launch of the new product line, the industry watches closely, anticipating how these changes will shape the future of peptide delivery.